UCB, a biopharmaceutical company, will present results from Phase 3 studies investigating the impact of bimekizumab on pain and health-related quality of life in moderate-to-severe hidradenitis suppurativa at the Symposium on Hidradenitis Suppurativa Advances. The data provide further evidence of bimekizumab’s potential to treat this chronic inflammatory condition. Despite promising results, the drug has not yet been approved by the US Food and Drug Administration.
Agentic AI could be a blessing and a curse for cybersecurity
Malwarebytes research shows that as agentic AI systems advance, they could become a significant tool for cybercriminals. This technology has the potential to be a
